DeepMed Research

BIIB-091

Generic Name: BIIB-091

Clinical Trials

A Study to Find Out How Different Forms of BIIB091 is Processed in The Body With and Without Food in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB091

First Posted Date: 2024-10-15

Last Posted Date: 2025-02-18

Lead Sponsor: Biogen

Target Recruit Count: 25

Registration Number: NCT06640933

Locations: 🇺🇸
PPD Las Vegas Research Unit, Las Vegas, Nevada, United States
🇺🇸
PPD Clinical Research Unit, Austin, Texas, United States

A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB091
Drug: Moxifloxacin
Drug: BIIB091-matched Placebo
Drug: Moxifloxacin-matched Placebo

First Posted Date: 2024-08-28

Last Posted Date: 2025-03-28

Lead Sponsor: Biogen

Target Recruit Count: 69

Registration Number: NCT06574828

Locations: 🇺🇸
Austin Clinic PPD, Austin, Texas, United States

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis

Phase 2

Recruiting

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Drug: DRF
Drug: BIIB091
Drug: Placebo

First Posted Date: 2023-04-04

Last Posted Date: 2025-03-13

Lead Sponsor: Biogen

Target Recruit Count: 275

Registration Number: NCT05798520

Locations: 🇺🇸
Vanderbilt MS Center, Nashville, Tennessee, United States
🇺🇸
HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸
Alta Bates Summit Medical Center, Berkeley, California, United States

and more 74 locations

Study of BIIB091 Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BIIB091
Drug: Rabeprazole
Drug: Itraconazole

First Posted Date: 2020-09-25

Last Posted Date: 2023-04-18

Lead Sponsor: Biogen

Target Recruit Count: 59

Registration Number: NCT04564612

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BIIB091
Drug: Placebo

First Posted Date: 2019-05-09

Last Posted Date: 2021-03-22

Lead Sponsor: Biogen

Target Recruit Count: 64

Registration Number: NCT03943056

Locations: 🇺🇸
Research Site, Dallas, Texas, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy